Considering the clinical heterogeneity of unfavourable neuroblastomas attributed to segmental chromosome alterations, additional gene alterations offering a survival advantage to MYCN-driven neuroblastoma are likely continually generated by NHEJ repair machinery. The gene discussed is MYCN; the disease is neuroblastoma.